Low‐dose gemcitabine plus nab‐paclitaxel <i>versus</i> standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase <scp>II</scp> trial
JGH open